TY - JOUR
T1 - European position paper on the management of patients with patent foramen ovale. General approach and left circulation thromboembolism
AU - Pristipino, Christian
AU - Sievert, Horst
AU - D'Ascenzo, Fabrizio
AU - Louis Mas, Jean
AU - Meier, Bernhard
AU - Scacciatella, Paolo
AU - Hildick-Smith, David
AU - Gaita, Fiorenzo
AU - Toni, Danilo
AU - Kyrle, Paul
AU - Thomson, John
AU - Derumeaux, Genevieve
AU - Onorato, Eustaquio
AU - Sibbing, Dirk
AU - Germonpré, Peter
AU - Berti, Sergio
AU - Chessa, Massimo
AU - Bedogni, Francesco
AU - Dudek, Dariusz
AU - Hornung, Marius
AU - Zamorano, Jose
AU - Omedè, Pierluigi
AU - Ballocca, Flavia
AU - Barbero, Umberto
AU - Giordana, Francesca
AU - Gili, Sebastiano
AU - Iannaccone, Mario
AU - Capodannno, Davide
AU - Valgimigli, Marco
AU - Byrne, Robert
AU - Akagi, Teiji
AU - Carroll, John
AU - Dalvi, Bharat
AU - Ge, Junbo
AU - Kasner, Scott
AU - Michel-Behnke, Ina
AU - Pedra, Carlos
AU - Rhodes, John
AU - Søndergaard, Lars
AU - Thomassen, Lars
AU - Biondi-Zoccai, Giuseppe G.L.
N1 - Funding Information:
fees from Boehringer Ingelheim, Bayer, Pfizer Bristol-Myers Squibb, Daiichi Sankyo, and Medtronic. P. Scacciatella reports personal fees from Abbott Medical and Gore Medical. J. Thomson reports being a proctor and consultant for Abbott Medical and Gore Medical. D. Hildick-Smith reports having consultancy/advocacy for Abbott, Gore and Occlutech. D. Sibbing reports personal fees outside the submitted work from Roche Diagnostics, Daiichi Sankyo, Eli Lilly, Bayer Healthcare, Sanofi, Pfizer and AstraZeneca. S. Kasner reports personal fees from Bristol-Myers Squibb, Boehringer Ingelheim, Medtronic and AbbVie, grants from W.L. Gore, and grants and personal fees from Janssen and Bayer, outside the submitted work. G. Biondi-Zoccai reports having been a consultant for Abbott Vascular and Bayer. J. Carroll reports personal fees from AGA Medical, St. Jude Medical, and Abbott. The Chairman of the task force and all the other authors have no conflicts of interest to declare. The Guest Editor has no conflicts of interest to declare.
Publisher Copyright:
© 2018 The Author(s).
PY - 2019/10/7
Y1 - 2019/10/7
N2 - The presence of a patent foramen ovale (PFO) is implicated in the pathogenesis of a number of medical conditions; however, the subject remains controversial and no official statements have been published. This interdisciplinary paper, prepared with involvement of eight European scientific societies, aims to review the available trial evidence and to define the principles needed to guide decision making in patients with PFO. In order to guarantee a strict process, position statements were developed with the use of a modified grading of recommendations assessment, development, and evaluation (GRADE) methodology. A critical qualitative and quantitative evaluation of diagnostic and therapeutic procedures was performed, including assessment of the risk/benefit ratio. The level of evidence and the strength of the position statements of particular management options were weighed and graded according to predefined scales. Despite being based often on limited and non-randomised data, while waiting for more conclusive evidence, it was possible to conclude on a number of position statements regarding a rational general approach to PFO management and to specific considerations regarding left circulation thromboembolism. For some therapeutic aspects, it was possible to express stricter position statements based on randomised trials. This position paper provides the first largely shared, interdisciplinary approach for a rational PFO management based on the best available evidence.
AB - The presence of a patent foramen ovale (PFO) is implicated in the pathogenesis of a number of medical conditions; however, the subject remains controversial and no official statements have been published. This interdisciplinary paper, prepared with involvement of eight European scientific societies, aims to review the available trial evidence and to define the principles needed to guide decision making in patients with PFO. In order to guarantee a strict process, position statements were developed with the use of a modified grading of recommendations assessment, development, and evaluation (GRADE) methodology. A critical qualitative and quantitative evaluation of diagnostic and therapeutic procedures was performed, including assessment of the risk/benefit ratio. The level of evidence and the strength of the position statements of particular management options were weighed and graded according to predefined scales. Despite being based often on limited and non-randomised data, while waiting for more conclusive evidence, it was possible to conclude on a number of position statements regarding a rational general approach to PFO management and to specific considerations regarding left circulation thromboembolism. For some therapeutic aspects, it was possible to express stricter position statements based on randomised trials. This position paper provides the first largely shared, interdisciplinary approach for a rational PFO management based on the best available evidence.
UR - http://www.scopus.com/inward/record.url?scp=85072956995&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85072956995&partnerID=8YFLogxK
U2 - 10.1093/eurheartj/ehy649
DO - 10.1093/eurheartj/ehy649
M3 - Article
C2 - 30141306
AN - SCOPUS:85072956995
SN - 0195-668X
VL - 40
SP - 3182
EP - 3195
JO - European Heart Journal
JF - European Heart Journal
IS - 38
ER -